Year 2011 Vol. 19 No 3

LECTURES, REVIEWS

MALINOVSKAYA I.I.

INHIBITORS OF THE VASCULAR ENDOTHELIAL GROWTH FACTOR IN TREATMENT OF DIABETIC MACULAR EDEMA

Diabetic retinopathy and its manifestation, diabetic macular edema, are one of the leading causes of blindness worldwide. In the last decade many papers have appeared proving the key role of the vascular endothelial growth factor (VEGF) in the etiopathogenesis of these diseases, its effect on the development of the retinal neovascularization and increased vascular permeability. This article focuses on the results of a new direction in the treatment of diabetic macular edema - intravitreal inhibitors of VEGF.

Keywords: vascular endothelial growth factor, diabetic macular edema, inhibitors of vascular endothelial growth factor
p. 118 125 of the original issue
References
  1. , . . / . . , . . // . VIII , , 14 2005 . ., 2005. . 88.
  2. Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Results of a randomized trial Diabetic Retinopathy Vitrectomy Study report 3 / Diabetic Retinopathy Vitrectomy Study Research Group // Ophthalmology. 1988. Vol. 95. P. 1307-1320.
  3. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1 / Early Treatment Diabetic Retinopathy Study Research Group // Arch. Ophthalmol. 1985. Vol. 103. P. 1796-1806.
  4. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic Macular Edema / R. Klein [et al.] // Ophthalmology. 1984. Vol. 91. P. 1464-1474.
  5. Ferris, F. Macular edema: a complication of diabetic retinopathy / F. Ferris, A. Patz // Surv. Ophthalm. 1984. Vol. 28. P. 452-461.
  6. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor / L. Aiello [et al.] // Diabetes. 1997. Vol. 46. P. 1473-1480.
  7. Pigment epithelium-derived factor: neurotrophic activity and identification as a member of the serine protease inhibitor gene family / F. R. Steele [et al.] // Proc. Natl. Acad. Sci. USA. 1993. Vol. 90. P. 1526-1530.
  8. Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor / K. Mori [et al.] // Invest. Ophthalmol. Vis. Sci. 2002. Vol. 43, N 7. P. 2428-2434.
  9. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptorspecific vascular endothelial growth factor mutants / H. Gille [et al.] // J. Biol. Chem. 2001. Vol. 276. P. 3222-3230.
  10. Expression, secretion, and age-related downregulation of pigment epithelium-derived factor, a serpin with neurotrophic activity / J. Tombran-Tink [et al.] // Neurosci. 1995. Vol. 15. P. 4992-5003.
  11. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema / D. W. Chun [et al.] // Ophthalmology. 2006. Vol. 113. P. 1706-1712.
  12. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema / Q. D. Nguyen [et al.] // Am. J. Ophthalmol. 2006. Vol. 142. P. 961-969.
  13. READ2 Study Group: Primary endpoint (6 months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study / Q. D. Nguyen [et al.] // Ophthalmology. 2009. Vol. 116. P. 2175-2178.
  14. RESOLVE Study Group: Safety and efficacy of ranibizumab treatment in patients with diabetic macular edema: 12-month results of the RESOLVE study / A. Wolf [et al.] // ARVO Meeting. Fort Lauderdable, 2009.
  15. Randomized trial evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema / M. J. Elman [et al.] // Ophthalmology. 2010. Vol. 117. P. 1064-1077.
  16. Macugen Diabetic Retinopathy Study Group: A phase II randomized double-masked trial of pegaptanib, an antivascular endothelial growth factor aptamer, for diabetic macular edema / E. T. Jr. Cunningham [et al.] // Ophthalmology. 2005. Vol. 112. P. 1747-1757.
  17. Changes in retinal neovascularization after pegaptanib therapy in diabetic individuals / A. P. Adamis [et al.] // Ophthalmology. 2006. Vol. 113. P. 23-28.
  18. Intravitreal injection of pegaptanib sodium for proliferative diabetic retinopathy / V. H. Gonzales [et al.] // Br. J. Ophthalmol. 2009. Vol. 93. P. 1474-1478.
  19. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (avastin) / J. Shahar [et al.] // Retina. 2006. Vol. 26. P. 262-269.
  20. Testing intravitreal toxicity of bevacizumab (avastin) / R. P. A. Manzano [et al.] // Retina. 2006. Vol. 26. P. 257-261.
  21. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema / I. U. Scott [et al.] // Ophthalmology. 2007. Vol. 114. P. 1860-1867.
  22. Efficacy of 1, 25 vs. 2, 5 mg intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial / D. S. Lam [et al.] // Retina. 2009. Vol. 29. P. 292-299.
  23. Long-term effect of intravitreal bevacizumab in patients with chronic diffuse diabetic macular edema / D. Kook [et al.] // Retina. 2008. Vol. 28 P. 1053-1060.
  24. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema / M. Soheilian [et al.] // Ophthalmology. 2009. Vol. 116. P. 1142-1150.
  25. Intravitreal bevacizumab in the treatment of proliferative diabetic retinopathy / R. L. Avery [et al.] // Ophthalmology. 2006. Vol. 113. P. 1695.el-15.
  26. Intravitreal bevacizumab for persistent new vessels in diabetic retinopathy (IBEPE study) / R. Jorge [et al.] // Retina. 2006. Vol. 26. P. 1006-1013.
  27. Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy / S. Moradian [et al.] // Graefes. Arch. Clin. Exp. Ophthalmol. 2008. Vol. 246. P. 1699-1705.
  28. Intravitreal bevacizumab and panretinal photocoagulation for proliferative diabetic retinopathy associated with vitreous haemorrhage / Y. H. Huang [et al.] // Retina. 2009. Vol. 29. P. 1134-1140.
  29. Cytokine traps: multi-component, high-affinity blocker of cytokine action / A. N. Economides [et al.] // Nat. Med. 2003. Vol. 9. P. 47-52.
  30. VEGF Trap: a VEGF blocker with potent antitumor effects / J. Holash [et al.] // Proc. Natl. Acad. Sci. USA. 2002. Vol. 99. P. 11393-11398.
  31. Stewart, M. W. Predicted biological activity of intravitreal VEGF Trap / M. W. Stewart, P. J. Rosenfeld // Br. J. Ophthalmol. 2008. Vol. 92. P. 667-668.
  32. An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-eye in patients with diabetic macular edema / D. V. Do [et al.] // Br. J. Ophthalmol. 2009. Vol. 93. P. 144-149.
  33. Singerman, L. J. Intravitreal bevasiranib in exudative age-related macular degeneration or diabetic macular edema / L. J. Singerman // 25-th Annual Meeting of the American Society of Retina Specialists, Indian Wells, December 15, 2007.
  34. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis / X. Zhu [et al.] // Am. J. Kidney. Dis. 2007. Vol. 49. P. 186-193.
  35. Scott, I. U. Reducing the risk of endophthalmitis following intravitreal injections / I. U. Scott, H. W. Jr. Flynn // Retina. 2007. Vol. 27. P. 10-12.
  36. Endophthalmitis associated with intravitreal antivascular endothelial growth factor therapy injections in an office setting / P. Suman [et al.] // Am. J. Ophthalmol. 2008. Vol. 145. P. 879-882.
  37. Pegaptanib for neovascular age-related macular degeneration / E. S. Gragoudas [et al.] // N. Engl. J. Med. 2004. Vol. 351. P. 2805-2816.
  38. Ranibizumab versus verteporfin for neovascular agerelated macular degeneration / D. M. Brown [et al.] // N. Engl. J. Med. 2006. Vol. 355. P. 1432-1444.
  39. Ranibizumab for neovascular agerelated macular degeneration / P. J. Rosenfeld [et al.] // N. Engl. J. Med. 2006. Vol. 355. P. 1419-1431.
Contacts | ©Vitebsk State Medical University, 2007-2023